RZLT Rezolute Inc
Price (delayed)
$3.02
Market cap
$182.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.22
Enterprise value
$175.82M
Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric
Highlights
RZLT's debt is down by 23% year-on-year and by 7% since the previous quarter
Rezolute's equity has decreased by 12% QoQ but it has increased by 9% YoY
Rezolute's EPS has decreased by 11% YoY but it has increased by 3.9% QoQ
Rezolute's quick ratio has decreased by 33% from the previous quarter and by 21% YoY
Rezolute's net income has decreased by 25% YoY and by 2.6% from the previous quarter
Key stats
What are the main financial stats of RZLT
Market
Valuations
Earnings
Shares outstanding
60.54M
Market cap
$182.82M
Enterprise value
$175.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$73.34M
Net income
-$71.13M
EBIT
-$71.13M
EBITDA
-$70.59M
Free cash flow
-$63.44M
Per share
Balance sheet
Liquidity
EPS
-$1.22
EPS diluted
-$1.22
Free cash flow per share
-$0.91
Book value per share
$1.72
Revenue per share
$0
TBVPS
$1.6
Total assets
$112.01M
Total liabilities
$12.42M
Debt
$1.93M
Equity
$99.59M
Working capital
$88.09M
Debt to equity
0.02
Current ratio
9.3
Quick ratio
9.1
Net debt/EBITDA
0.1
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-62.4%
Return on equity
-70.3%
Return on invested capital
-85.3%
Return on capital employed
-70.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RZLT stock price
How has the Rezolute stock price performed over time
Intraday
3.42%
1 week
10.62%
1 month
-31.83%
1 year
31.88%
YTD
-38.37%
QTD
4.14%
Financial performance
How have Rezolute's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$73.34M
Net income
-$71.13M
Gross margin
N/A
Net margin
N/A
Rezolute's net income has decreased by 25% YoY and by 2.6% from the previous quarter
Rezolute's operating income has decreased by 17% YoY and by 2.6% from the previous quarter
Growth
What is Rezolute's growth rate over time
Valuation
What is Rezolute stock price valuation
P/E
N/A
P/B
1.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rezolute's EPS has decreased by 11% YoY but it has increased by 3.9% QoQ
The stock's price to book (P/B) is 15% less than its last 4 quarters average of 2.0 but 6% more than its 5-year quarterly average of 1.6
Rezolute's equity has decreased by 12% QoQ but it has increased by 9% YoY
Efficiency
How efficient is Rezolute business performance
The company's return on invested capital fell by 46% YoY
The ROE is down by 36% year-on-year
RZLT's return on assets is down by 30% year-on-year
Dividends
What is RZLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RZLT.
Financial health
How did Rezolute financials performed over time
Rezolute's current ratio has decreased by 33% from the previous quarter and by 23% YoY
Rezolute's quick ratio has decreased by 33% from the previous quarter and by 21% YoY
RZLT's debt is 98% smaller than its equity
RZLT's debt to equity is down by 33% year-on-year
RZLT's debt is down by 23% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.